A phase II study of cisplatin and irinotecan induction chemotherapy, followed by ZD 1839 (IRESSA) [gefitinib] in adult patients with surgically unresectable and/or metastatic esophageal or gastric carcinomas.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Cisplatin (Primary) ; Gefitinib (Primary) ; Irinotecan (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 12 Jan 2012 Actual end date (1 May 2007) added as reported by ClinicalTrials.gov
- 12 Jan 2012 Actual patient number (21) added as reported by ClinicalTrials.gov.
- 12 Jan 2012 Status changed from discontinued to completed as reported by ClinicalTrials.gov.